Opus Genetics' LCA5 Gene Therapy Restores Vision in Pediatric Patients; BEST1 Data Also Positive
IRD has more than doubled off its 52-week low of $0.901.
Summary
Opus Genetics announced positive clinical and preclinical data at ARVO 2026, highlighting significant pipeline advancements. Six-month Phase 1/2/3 clinical data for OPGx-LCA5 demonstrated robust restoration of cone-mediated vision, over 30-fold improvements in cone sensitivity, and improved visual acuity in pediatric patients with severe LCA5. Additionally, early Phase 1b/2a data for OPGx-BEST1 showed visual acuity gains and improved retinal structure, while preclinical RHO programs indicated durable retinal preservation. This news provides strong validation for the company's gene therapy platform and significantly de-risks its pipeline, building on the 'significant clinical progress' noted in its last 10-K. Investors will now focus on upcoming milestones, including the 3-month topline data for OPGx-BEST1 Cohort 1 expected in September 2026.
At the time of this announcement, IRD was trading at $5.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $382.7M. The 52-week trading range was $0.90 to $5.81. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.